Splanchnic Nerve Anesthesia in Heart Failure
| Status: | Completed |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 90 |
| Updated: | 1/18/2019 |
| Start Date: | January 1, 2017 |
| End Date: | December 2018 |
Splanchnic Nerve Block for Acute Heart Failure
Patients admitted for acute heart failure and undergoing right heart catheterization will be
enrolled in this study. Subjects will undergo catheterization of the heart to obtain central
cardiac pressure and other cardiac hemodynamic parameters. Subsequently, the subject will
undergo a regional nerve block of the splanchnic nerves. Patients will remain in the
catheterization lab for the duration of anesthetic block and will be continuously
hemodynamically monitored.
This study will be a prospective, uncontrolled clinical trial. The study will not be
controlled as invasive monitoring of hemodynamics will be performed, allowing clear
demonstration of a cause-effect relationship. The goal of the study is to provide proof of
concept.
enrolled in this study. Subjects will undergo catheterization of the heart to obtain central
cardiac pressure and other cardiac hemodynamic parameters. Subsequently, the subject will
undergo a regional nerve block of the splanchnic nerves. Patients will remain in the
catheterization lab for the duration of anesthetic block and will be continuously
hemodynamically monitored.
This study will be a prospective, uncontrolled clinical trial. The study will not be
controlled as invasive monitoring of hemodynamics will be performed, allowing clear
demonstration of a cause-effect relationship. The goal of the study is to provide proof of
concept.
Inclusion Criteria:
- Diagnosis of heart failure (HF)
- Prior admissions for decompensated HF
- Symptomatic with dyspnea with clinical, radiographic or echocardiographic signs of
fluid overload
- On a stable HF drug regimen prior to admission
- Anticipated hospital stay of at least 2 nights following catheterization procedure
Exclusion Criteria:
- Ongoing treatment with oral anticoagulation other than aspirin
- Immunosuppressive medications for solid organ transplant
- Acute MI (STEMI or NSTEMI) within 7 days
- Evidence of cardiogenic shock within 48 hours
- Systolic blood pressure < 90 mmHg or >180 mmHg
- Restrictive or constrictive cardiomyopathy
- Chronic kidney disease stage 3 or higher due to primary renal pathology
- Pregnancy
We found this trial at
1
site
Click here to add this to my saved trials
